Show results for
Refine by
Solid Tumor Equipment & Supplies In Kosovo
187 equipment items found
by:AbelZeta Inc. based inRockville, MARYLAND (USA)
PRODUCT: C-CAR036. INDICATION: Solid Tumor. PLATFORM: CAR-T. PRECLINICAL: Claudin 18.2. IIT: -. PHASE 1/1B: -. PHASE 2: -. PARTNERS: ...
by:AbelZeta Inc. based inRockville, MARYLAND (USA)
PRODUCT: C-CAR031. INDICATION: HCC. PLATFORM: CAR-T. PRECLINICAL: GPC3. IIT: -. PHASE 1/1B: -. PHASE 2: -. PARTNERS: ...
Manufactured by:T-Knife GmbH based inBerlin, GERMANY
TK-8001 is a CD8 TCR-T specific for the Melanoma-associated Antigen Gene-A1, or MAGE-A1. MAGE-A1 is associated with hallmarks of aggressive cancers and poor clinical prognosis, and there is an emerging body of evidence indicating its involvement as a potential driver of tumorigenesis. MAGE-A1 represents an attractive therapeutic target given the high unmet need in MAGE-A1 expressing cancers, no ...
Manufactured by:LGC SeraCare based inMilford, MASSACHUSETTS (USA)
The Seraseq Tumor Mutation DNA Mix v2 (AF7) HC is a multiplexed mixture of actionable biosynthetic DNA targets precisely blended with a single, well-characterized genomic background. This product is produced under rigorous design control and manufacturing practices to an allelic frequency of 7%, and is offered in a high concentration (HC) format at 25 ng/µL. Designed to assess the overall ...
Manufactured by:LGC SeraCare based inMilford, MASSACHUSETTS (USA)
Whole transcriptome RNA sequencing allows for the analysis of fusion genes with potential clinical utility that currently cannot be detected using the limited genomic coverage of targeted NGS panels. Additionally, some clinical cancer testing labs are evaluating whole transcriptome panels for improved diagnostic yields and clinical utilization for NGS-based tumor profiling test reimbursements. ...
Manufactured by:Taiho Oncology, Inc. based inPrinceton, NEW JERSEY (USA)
ERBB inhibitor for Solid Tumors PHASE ...
Manufactured by:Cartherics Pty ltd based inNotting Hill, AUSTRALIA
Indication: Solid tumors. Research: Descriptor iNK cells [other CAR targets / dual ...
Manufactured by:Cartherics Pty ltd based inNotting Hill, AUSTRALIA
Indication: Solid tumors. Research: CAR iNK cells + novel receptor fusion proteins. ...
Manufactured by:Taiho Oncology, Inc. based inPrinceton, NEW JERSEY (USA)
S6K, AKT, RSK inhibitor for Solid Tumors PHASE ...
Manufactured by:Cartherics Pty ltd based inNotting Hill, AUSTRALIA
Indication: Solid tumors. Research: iT cells and macrophages [CARs+/- gene KOs]. ...
Manufactured by:The Menarini Group based inFlorence, ITALY
SL-901 is an oral small molecule PI3K and DNA-PK inhibitor that has demonstrated activity against PI3K α/δ and PIK3C2 β. SL-901 has shown preclinical activity against a variety of tumor types. A Phase 1 trial in patients with solid tumors is currently ...
Manufactured by:Taiho Oncology, Inc. based inPrinceton, NEW JERSEY (USA)
Tumors with specific FGFR aberrations: Solid tumors, Gastric cancer, Myelolymphoid neoplasms PHASE ...
Manufactured by:Adaptimmune LLC based inPhiladelphia, PENNSYLVANIA (USA)
Our ADP-A2M4 (MAGE-A4) SPEAR T-cell therapy is directed to a member of the MAGE family of cancer testis antigen expressed in a number of solid tumor cell types. The MAGE- A4 antigen is among the most commonly expressed cancer-testis antigens. We are conducting various trials with the ADP-A2M4 SPEAR T-cell in various solid ...
by:Stemline Therapeutics, Inc. based inNew York, NEW YORK (USA)
SL-801 is a structurally novel, oral, small molecule, reversible inhibitor of exportin-1 (XPO1), a nuclear transport protein implicated in both solid tumors and hematologic malignancies. SL-801 has demonstrated preclinical in vitro and in vivo antitumor activity against a wide array of solid and hematologic cancers. SL-801’s potential ...
Manufactured by:Senti Biosciences based inSouth San Francisco, CALIFORNIA (USA)
The product profile of SENTI-301 has the potential to promote expansion and persistence of NK cells, and activate and recruit the body’s own immune cells into the solid tumor microenvironment for enhanced anti-tumor activity. ...
by:Celluris based inSão Paulo, BRAZIL
The chimeric T cell antigen receptor therapy, also known as CAR-T, is an immunotherapy that is innovating the treatment of hematological and solid tumors. This new technology is considered less aggressive than conventional treatments, since it focuses only on cancer cells, not attacking healthy ...
Manufactured by:Adaptimmune LLC based inPhiladelphia, PENNSYLVANIA (USA)
Our ADP-A2M4CD8 SPEAR T-cell therapy is our first "next-generation" therapy and is directed to MAGE-A4, a member of the MAGE family of cancer-testis antigens expressed in a number of solid tumor types. What differentiates this therapy from our ADP-A2M4 SPEAR T-cells is that these cells also express the CD8α co-receptor alongside the engineered TCR that ...
Manufactured by:Boston Pharmaceuticals based inCambridge, MASSACHUSETTS (USA)
BOS172738 is a highly selective, reversible, ATP-competitive RET (Rearranged during Transfection) kinase inhibitor. RET rearrangements and activating mutations are found in multiple solid tumors, but especially with non-small cell lung cancers and medullary thyroid carcinomas. ...
Manufactured by:Affimed GmbH based inHeidelberg, GERMANY
The proprietary ROCK platform enables a tumor-targeted approach that can be tailored across hematological and solid tumors. The ROCK (Redirected Optimized Cell Killing) platform allows for a modular approach to generating customizable ICE (innate cell engager) molecules. High-affinity ICE (innate cell engager) molecules, which are created using ...
Manufactured by:Adaptimmune LLC based inPhiladelphia, PENNSYLVANIA (USA)
Our ADP-A2M10 (MAGE-A10) T-cell therapy is directed to a member of the MAGE family of cancer testis antigens expressed in a number of solid tumor cell types. Any expression in cancer is often associated with higher grade tumors. Please note that the two trials with ADP-A2M10 are now closed for ...